Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Group 1 - Alkermes plc will participate in a webcast panel discussion on "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025 [1] - The live webcast will be accessible under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [2] - The company is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]